Contract drug maker Catalent to double production of Moderna COVID vaccine: WSJ

Catalent Inc. , a contract drug manufacturer, is expanding U.S. production of the COVID-19 vaccine developed by Moderna Inc. and will nearly double production at its Bloomington, Ind. plant to about 400 vials a minute in April, the Wall Street Journal reported Tuesday, citing people familiar with the matter. The plant will be able to make an additional 80 million vials a year and will start shipping new doses in May, the people said. The move will help Moderna reach its target of delivering an additional 100 million doses to the U.S. government by end May and another 100 million by end-July. Moderna shares were up 0.6% premarket and have gained 24% in the year to date, while the S&P 500 has gained 8.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.